Interstitial cystitis\/bladder pain syndrome (ICBPS) is a disorder characterized by chronic pain, discomfort, and pressure in the pelvic region that often includes symptoms of urinary frequency and urgency. Janssen\/bene-Arzneimittel\u2019s\u00a0Elmiron and Mylan\u2019s\u00a0intravesical dimethyl sulfoxide (RIMSO-50) are the only two pharmacological treatments approved for ICBPS, but other antihistamines, antidepressants, and antiepileptics\u00a0may be\u00a0used off-label to ameliorate symptoms. Because pharmacological treatments are usually only partially effective, they are often combined with nonpharmacological therapies in a trial-and-error approach. As such, substantial unmet need persists for more effective treatment options.<\/p>\n
QUESTIONS ANSWERED<\/strong><\/p>\n PRODUCT DESCRIPTION<\/strong><\/p>\n Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n Markets covered:<\/strong> United States, United Kingdom, France, Germany.<\/p>\n Primary research: <\/strong>Survey of 60 U.S. and 30 European urologists fielded in March 2018.<\/p>\n Key companies: <\/strong>bene-Arzneimittel, Janssen,\u00a0Mylan, Pfizer.<\/p>\n Key drugs: <\/strong> Elmiron, amitriptyline, hydroxyzine, duloxetine, Lyrica, gabapentin, intravesical medications (lidocaine, heparin, dimethyl sulfoxide, hyaluronic acid, others).<\/p>\n Key metrics included:<\/strong><\/p>\n\n
\n